ArticleBiomarkers in medicine2025
MicroRNA-140-5p and cystatin-C expression in patients with vascular cognitive impairment and its clinical value.
Article in Biomarkers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVascular cognitive impairment (VCI) is a cerebrovascular disease leading to mental decline. Appropriate biomarkers must be identified to facilitate the diagnosis of VCI. Therefore, we investigated changes in miR-140-5p and cystatin-C (Cys-C) expression in the serum of patients with VCI.
methodsThe miR-140-5p or Cys-C serum expression levels were determined using real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR) or immunoturbidimetry. MMP-9 and IL-6 expression were detected in both groups. Correlations between serum-exhaled miR-140-5p or Cys-C and IL-6 or MMP-9 were analyzed using Pearson's method. A receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of miR-140-5p, Cys-C, and miR-140-5p combined with Cys-C for diagnosing VCI.
resultsmiR-140-5p and Cys-C serum levels were significantly upregulated in patients with VCI, and the increase was more pronounced in patients with vascular dementia (VaD). In addition, miR-140-5p and Cys-C positively correlated with increased IL-6 and MMP-9 expression. The ROC analysis showed that the combination of miR-140-5p and Cys-C demonstrated the AUC was 100.0% (sensitivity: 100%; specificity, 98.3%).
conclusionThe upregulation of miR-140-5p and Cys-C indicates that miR-140-5p and Cys-C may be related VCI development. The combined diagnosis of miR-140-5p has potential diagnostic value for diagnosis and screening of VCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.